What does cytoplasmic staining with a negative Antinuclear Antibody (ANA) mean?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Cytoplasmic staining with a negative ANA test result indicates the presence of antibodies targeting cytoplasmic components, which can be associated with various autoimmune conditions, and further specific antibody testing is recommended for diagnosis. This pattern occurs when the immune system produces antibodies that target cytoplasmic structures instead of nuclear materials, as noted in the international recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies 1. The ANA test is technically negative because ANA specifically refers to antibodies against nuclear components, but the cytoplasmic staining pattern is still clinically significant.

Clinical Significance

The finding of cytoplasmic staining can be associated with certain autoimmune conditions such as:

  • Autoimmune liver diseases (primary biliary cholangitis, autoimmune hepatitis)
  • Myositis (muscle inflammation)
  • Certain vasculitis syndromes It may also be seen with anti-mitochondrial antibodies or anti-ribosomal P antibodies, as suggested by the recommendations for ANA testing and interpretation 1.

Diagnostic Approach

If a cytoplasmic staining pattern with a negative ANA test result is obtained, further specific antibody testing is typically recommended to identify the exact target of these antibodies. The pattern and specific antibody type can help determine if an underlying autoimmune condition requiring treatment is present. This finding should be interpreted in the context of symptoms and other laboratory results, as cytoplasmic staining can occasionally occur in healthy individuals without clinical significance, highlighting the importance of standardized terminology and reporting of ANA-IIFA patterns 1.

Reporting and Interpretation

According to the guidelines, ANA-IIFA patterns should be reported according to standardized terminology, and besides nuclear patterns, cytoplasmic and mitotic apparatus patterns should be reported and specified when possible 1. This ensures that the clinical significance of cytoplasmic staining with a negative ANA test can be accurately assessed and appropriate further testing or treatment can be initiated.

From the Research

Cytoplasmic Staining but Negative ANA

  • Cytoplasmic staining refers to the presence of antibodies that target the cytoplasm of cells, which can be detected through indirect immunofluorescence microscopy 2, 3.
  • A negative antinuclear antibody (ANA) test does not necessarily indicate the absence of autoantibodies, as some individuals may have cytoplasmic staining but negative ANA results 3.
  • In patients with antisynthetase syndrome, cytoplasmic staining can be a useful screening test, even when ANA results are negative 3.
  • The presence of cytoplasmic staining can be associated with specific autoantibody patterns, such as reticular or speckled patterns, which can be relevant to the diagnosis of autoimmune diseases 2.

Clinical Implications

  • A negative ANA result should not be used to exclude the diagnosis of antisynthetase syndrome or other autoimmune diseases, as cytoplasmic staining can be a relevant marker 3.
  • The evaluation of cytoplasmic staining patterns can provide valuable information for the diagnosis and characterization of autoimmune diseases, particularly in cases where ANA results are negative 2, 3.
  • Further studies are needed to fully understand the clinical significance of cytoplasmic staining and its relationship to autoimmune diseases 4, 5, 6.

Related Questions

What is the significance of a positive Antinuclear Antibody (ANA) result of 1:80 with a nuclear membrane pattern in an asymptomatic patient and are further tests needed?
What are the next steps for a patient with a positive Antinuclear Antibody (ANA) result of 1:2.3?
What are the next steps for a patient with a positive Antinuclear Antibody (ANA) test result?
What is the management approach for a patient who tests positive for Antinuclear Antibody (ANA)?
What does a positive Antinuclear Antibody (ANA) test at a titer of 1:80 indicate?
Is clonidine (antihypertensive medication) still used for treating hypertensive emergencies in an office setting?
What are the differential diagnoses for a patient with persistently elevated Immunoglobulin G4 (IgG4) levels, normocytic anemia, and chronic, non-healing skin lesions with distinctive firm, white borders, in the context of normal immunoglobulin levels, absence of eosinophilia, and unexplained weight loss?
What is the interpretation of the following complete blood count (CBC) results: White Blood Cell (WBC) count of 7.4 x10^3/μL, Red Blood Cell (RBC) count of 4.98 x10^6/μL, Hemoglobin of 16.0 g/dL, Hematocrit of 47.2%, Mean Corpuscular Volume (MCV) of 95 fL, Mean Corpuscular Hemoglobin (MCH) of 32.1 pg, Mean Corpuscular Hemoglobin Concentration (MCHC) of 33.9 g/dL, Red Cell Distribution Width (RDW) of 12.4%, Platelet count of 449 x10^3/μL, and differential counts showing Neutrophils of 65%, Lymphocytes (Lymphs) of 17%, Monocytes of 15%, Eosinophils (Eos) of 2%, and Basophils (Basos) of 1%?
What are the differential diagnoses for a patient with persistently elevated Immunoglobulin G4 (IgG4) levels, normocytic anemia, and chronic, non-healing skin lesions with distinctive firm, white borders, in the context of normal immunoglobulin A (IgA), immunoglobulin E (IgE), and immunoglobulin M (IgM) levels, and lack of response to broad-spectrum antibiotics, including Bactroban (mupirocin) and topical steroids?
What is the difference between Wolff-Parkinson-White (WPW) syndrome, Atrioventricular Reentrant Tachycardia (AVRT) and Atrioventricular Nodal Reentrant Tachycardia (AVNRT)?
What are the optimal doses of valsartan and spironolactone to achieve Guideline-Directed Medical Therapy (GDMT) in patients with Chronic Heart Failure with Reduced Ejection Fraction (CHFrEF)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.